50 results about "Indole-3-carbinol" patented technology

New compositions are disclosed that comprise the phytochemical Diindolylmethane (DIM), as well as its precursor, Indole-3-carbinol (I3C), and cogener, 2-(Indol-3-ylmethyl)-3,3'diindolylmethane (LTR-1), acceptable carriers and/or excipients. These compositions are administered to prevent or reduce symptoms associated with mastalgia and endometriosis.

The invention relates to non-surgical methods for treating cervical or vaginal neoplasia including cervical intraepithelial neoplasia, intraepithelial neoplasia, vulvar intraepithelial neoplasia and ano-genital warts. The treatment, which utilizes an effective amount of indole-3-carbinol and/or diindolylmethane, is effective whether or not the patient is also infected with human papillomavirus, the most common sexually transmitted viral disease in the United States and a known risk factor for both cervical intraepithelial neoplasia and cervical cancer.

Compounds useful as antibacterial agents are provided. The compounds are analogs of indole-3-carbinol and have a backbone selected from dihydroindolo[2,3-b]carbazole, 2,2′-diindolylmethane, 2′,3-diindolylmethane, and 3,3′-diindolylmethane. The compounds are useful therapeutic and prophylactic treatment of bacterial infections in mammals. Methods of synthesis of the compounds are provided, as are pharmaceutical compositions containing the compounds.

The invention provides new application of indole-3-carbinol, diindolyl methane and derivatives thereof in preparation of medicaments for treating osteoporosis. The indole-3-carbinol (I3C), the diindolyl methane (DIM) and the derivative compounds thereof can inhibit growth and functions of osteoclasts through medicaments, and can be used for preventing and treating the osteoporosis in principle. The DIM, the I3C and the derivative compounds can effectively reduce the pathogenetic symptoms of osteoporosis animal models, and can be used as candidate medicament molecules for treating the osteoporosis. Meanwhile, the adopted small molecular substances are easily obtained, are low in price, stable in properties and convenient for storage and transportation, and have broad application prospect.

Compounds and methods for treating cancer and inducing apoptosis in unwanted rapidly proliferating cells. The compounds are shown in formula I:

wherein X is hydroxyl or amino; Y is carboxyl or sulfonyl; R₁, R₂, R₃, and R₄ can be the same or different and are selected from hydrogen, halogen, methoxy, trifluoromethyl, hydroxyl and combinations thereof, R₅, R₆, and R₇ may be the same or different and are selected from hydrogen, chloro, bromo, nitro, phenyl, amino, methoxy, and combinations thereof, and derivatives or metabolites thereof.

Novel metabolites and enzymes involved in skatole metabolism are disclosed. The novel metabolites are 3-OH-3-methylindolenine (HMI); 3-methyloxindole (3MOI); indole-3-carbinol (I-3C); and 2-aminoacetophenone (2-AM). Measuring levels of these metabolites in a pig may be useful in identifying the pig's ability to metabolize skatole and its susceptibility to boar taint. The novel enzymes involved in skatole metabolism are aldehyde oxidase and CYP2A6. Enhancing the activity of these enzymes may be useful in enhancing skatole metabolism and reducing boar taint. The identification of the enzyme also allows the development of screening assays for substances that interact with these enzymes and skatole metabolism or for genetic screening to identify pigs on the basis of their skatole metabolism. Pigs having high levels of these enzymes may be selected and bred to produce pigs that have a lower incidence of boar taint.

Provided herein are pharmaceutical compositions and methods for treating disorders characterized by reduced expression of anti-oxidative stress enzymes in a subject. In one aspect, the present invention provides a method for inducing expression of anti-oxidative stress enzymes in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of a demethylating agent. The demethylating agent includes a phytochemical that induces expression of Nrf2 and Nrf2-mediated genes expressing anti-oxidative stress. Such phytochemicals include indoles, such as 3,3′-diindolylmethane (DIM) and indole-3-carbinol (I3C), and isothiocyanates, such as phenethyl isothiocyanate (PEITC) and sulforaphane (SFN).

The invention belongs to the technical field of biological medicine, specifically relates to an application of diindolylmethane, a precursor compound indole-3-carbinol, and diindolylmethane derivatives in preparation of drugs for treating liver fibrosis, hepatitis and liver cirrhosis-related liver diseases. With the indole-3-carbinol, the diindolylmethane and the diindolylmethane derivatives, thebody can be effectively prevented from damage due to free radical, such that free radical induced stellate cell activation and associated collagen expression are prevented so as to reduce the degree of the liver fibrosis. Therefore, the indole-3-carbinol, the diindolylmethane and the diindolylmethane derivatives can be provided for treating the fibrosis-related liver fibrosis, the hepatitis and the liver cirrhosis diseases.

A pharmaceutical composition for the treatment of an estrogen-dependent disease or condition comprises: (1) at least one polysaccharide selected from the group consisting of an alginate and a fucoidan in a quantity effective to treat an estrogen-dependent disease or condition; and (2) a pharmaceutically acceptable carrier. The composition can include both an alginate and a fucoidan. The composition can include other ingredients such as at least one compound selected from the group consisting of diindolylmethane and indole-3-carbinol in a quantity sufficient to inhibit the activity of estrogen. Methods for use of the composition for the treatment of an estrogen-dependent disease or condition, especially endometriosis, are described.

The invention relates to the field of medicines and particularly relates to an application of indole-3-carbinol. The indole-3-carbinol is introduced to vascular aging preventing researches and is expected to delay progression of diseases, such as coronary heart disease, cerebral apoplexy and Alzheimer disease, related to vascular aging such as atherosclerosis, to prolong lifetime and to promote health of the aged. The indole-3-carbinol in a scheme is convenient to use and low in treatment cost, and lays a foundation for treatment of cardiovascular and cerebtovascular disease related to vascular aging such as atherosclerosis by utilizing the I3C and oligomer medicines thereof.

The invention provides new application of indole-3-carbinol (I3C), diindolyl methane (DIM) and derivative compounds thereof in preparation of medicaments for treating senile dementia. By improving the expression of intracellular free radical resistant specific genes, the medicaments can enhance the automatic free radical clearing capacity of cells and lighten the harm of free radicals to the cells and tissues. The DIM, the I3C and the derivative compounds can effectively reduce the pathogenetic symptoms of senile dementia animal models, obviously improve the dyskinesia of SAM-P/8 mice, obviously improve the superoxide dismutase (SOD) activity of brain tissues of the SAM-P/8 mice, reduce the methylene dioxyamphetamine (MDA) content of brain tissues, reduce the choline esterase activity of the brain tissues and enhance the activities of Na<+>-K<+>-ATP enzyme and Ca<2+>-ATP enzyme of the brain tissues, so the DIM, the I3C and the derivative compounds can be used as candidate medicament molecules for treating the senile dementia. Meanwhile, the adopted small molecular substances are easily obtained, are low in price, stable in properties and convenient for storage and transportation, and have broad application prospect.

The invention provides 2-(((1H-indole-3-yl) methoxyl) methyl)-1H-benzimidazole derivatives represented as a general formula shown in the specification. Substituent groups R1 and R7 in the formula can be -H, -CH3, -CH2CH3, -CHCH=CH2, -CH2Ph, -COCH3 and p-CH3-C6H4-SO2-; R2, R3, R4, R5, R6, R8, R9, R10 and R11 can be -H, -CH3, -CH2CH3, -CHCH=CH2, -CH2Ph,-COCH3, -CF3, -CCl3, -CN, -NHCH3, -NO2, -OCH3, -CH2NH2, -COOCH3 and -CONHCH3. According to a method, indole-3-methanol, a derivative of indole-3-methanol, 2-chloromethylbenzimidazole and a derivative of 2-chloromethylbenzimidazole are adopted as reactants, or 3-chloromethyl indole, a derivative of 3-chloromethyl indole, benzimidazole-2-methanol and a derivative of benzimidazole-2-methanol are adopted as the reactants, the reactants have a one-step reaction under the conditions of an appropriate solvent and an appropriate catalyst, and the 2-(((1H-indole-3-yl) methoxyl) methyl)-1H-benzimidazole derivatives are generated. The preparation of the compounds is shown in the specification, wherein an X group in the formula is chlorine, bromine or iodine.

A composition comprising indole-3-carbinol, milk thistle, schizandra, stinging nettle, hydroxymatairesinol ligands and optionally calcium-d-glucarate and 400 KJ Vitamin D for altering urinary estrone metabolite and preventing breast cancer in pre and post menopausal women

The invention provides application of indole-3-methanol, diindolylmethane and derivatives thereof in drugs used for treating psoriasis. Indole-3-methanol, diindolylmethane and the derivatives thereof can be used for treating psoriasis by inhibiting mitosis of basal cells. Indole-3-methanol, diindolylmethane and the derivatives thereof can effectively mitigate symptoms of psoriasis and can be used as candidate drug molecules for treatment of psoriasis. Meanwhile, micromolecular drugs used in the invention are easily available, low in price, stable in properties and convenient to store and transport, and have wide application prospects.